scispace - formally typeset
Z

Zygmunt Kazimierczuk

Researcher at Warsaw University of Life Sciences

Publications -  131
Citations -  3305

Zygmunt Kazimierczuk is an academic researcher from Warsaw University of Life Sciences. The author has contributed to research in topics: Glycosylation & Benzimidazole. The author has an hindex of 27, co-authored 130 publications receiving 3114 citations. Previous affiliations of Zygmunt Kazimierczuk include Polish Academy of Sciences & University of Osnabrück.

Papers
More filters
Journal ArticleDOI

The selectivity of inhibitors of protein kinase CK2: an update.

TL;DR: DMAT and its parent compound TBI are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus), and TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3.
Journal ArticleDOI

2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2

TL;DR: A novel compound, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), is described, which is superior to the commonly used specific CK2 inhibitor 4, 5, 6, 7-t Petrabromobenzotriazoles (TBB) in several respects and is the first choice CK2 inhibitors for in vivo studies available to date.
Journal ArticleDOI

Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.

TL;DR: It is proposed to adopt 2c as first choice CK2 inhibitor instead of TBB, especially for in cell studies, because 2c is even more susceptible than TBB to mutations of the unique hydrophobic residues V66 and/or I174 to alanine.
Journal ArticleDOI

Syn-anti conformational analysis of regular and modified nucleosides by 1D 1H NOE difference spectroscopy: a simple graphical method based on conformationally rigid molecules

TL;DR: In this paper, the 1D 1 H NOE difference spectra of 50 base and/or sugar-modified nucleosides were measured in (CD 3 ) 2 SO with irradiation of various protons.